PMID- 26609908
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20170303
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 21
IP  - 10
DP  - 2016 Oct
TI  - Influence and analysis of low-dosage steroid therapy in severe aristolochic acid 
      nephropathy patients.
PG  - 835-40
LID - 10.1111/nep.12684 [doi]
AB  - AIM: To investigate the effect of low-dosage steroid therapy in patients with 
      severe aristolochic acid nephropathy (AAN). METHODS: Forty-three chronic AAN 
      patients in the Peking Union Medical College Hospital and the First Affiliated 
      Hospital of Xinxiang Medical College were included in this study from November 
      1998 to October 2013. According to the treatment method, the patients were 
      divided into a steroid group (SG, n = 25) and a control group (CG, n = 18). The 
      serum biochemical indicators at the basement in the two groups exhibited no 
      obvious statistical differences. In comparison with the baseline data, the levels 
      of serum creatinine at 3, 6, 9, and 12 months were analyzed. The blood pressure, 
      haemoglobin, serum biochemical indicators, and the side-effects of steroid 
      application were also observed. Urinary macrophage chemoattractant protein-1 
      (MCP-1) and transforming growth factor-1 (TGF-1) amounts were measured as well. 
      RESULTS: (i) The serum creatinine content in the CG group was significantly 
      higher than the baseline level during the follow-up(6, 9, and 12 months later), 
      whereas in the SG group it decreased during the 3-6 month period and remained 
      stable within 1 year. (ii) The biochemical indicators, blood pressure, and 
      haemoglobin persisted stable. (iii) The side-effects of low-dosage steroid 
      therapy were not severe and were tolerated by the AAN patients. (4) Urinary MCP-1 
      and TGF-1 concentrations were positively correlated with serum creatinine and 
      decreased in the SG group. CONCLUSION: Low-dosage steroid therapy reversed or 
      delayed the renal failure progression in severe chronic AAN patients, which may 
      be associated with the suppression of MCP-1 and TGF-beta1 activities.
CI  - (c) 2016 Asian Pacific Society of Nephrology.
FAU - Ma, Dong-Hong
AU  - Ma DH
AD  - Department of Nephrology, Peking Union Medical College Hospital, Beijing, China.
AD  - Department of Nephrology, the First Affiliated Hospital of Xinxiang Medical 
      University, Weihui, Hen Nan, China.
FAU - Zheng, Fa-Lei
AU  - Zheng FL
AD  - Department of Nephrology, Peking Union Medical College Hospital, Beijing, China. 
      zhengfl46@vip.sina.com.
FAU - Su, Ying
AU  - Su Y
AD  - Department of Nephrology, Peking Union Medical College Hospital, Beijing, China.
FAU - Li, Ming-Xi
AU  - Li MX
AD  - Department of Nephrology, Peking Union Medical College Hospital, Beijing, China.
FAU - Guo, Ming-Hong
AU  - Guo MH
AD  - Department of Nephrology, the First Affiliated Hospital of Xinxiang Medical 
      University, Weihui, Hen Nan, China.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Aristolochic Acids)
RN  - 0 (Chemotactic Factors)
RN  - 0 (Glucocorticoids)
RN  - 0 (Transforming Growth Factor beta1)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Aged
MH  - Aristolochic Acids/*adverse effects
MH  - Chemotactic Factors/blood
MH  - China
MH  - Creatinine/blood
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Drug Monitoring/methods
MH  - Female
MH  - Follow-Up Studies
MH  - *Glucocorticoids/administration & dosage/adverse effects
MH  - Humans
MH  - *Kidney Failure, Chronic/blood/chemically induced/diagnosis/drug therapy
MH  - Kidney Function Tests/methods
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Statistics as Topic
MH  - Transforming Growth Factor beta1/blood
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aristolochic acid nehropathy
OT  - macrophage chemoattractant protein-1
OT  - steroid
OT  - transforming growth factor
EDAT- 2015/11/27 06:00
MHDA- 2017/03/04 06:00
CRDT- 2015/11/27 06:00
PHST- 2015/09/02 00:00 [received]
PHST- 2015/11/08 00:00 [revised]
PHST- 2015/11/22 00:00 [accepted]
PHST- 2015/11/27 06:00 [entrez]
PHST- 2015/11/27 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
AID - 10.1111/nep.12684 [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2016 Oct;21(10):835-40. doi: 10.1111/nep.12684.